TNF and viral infectious disease: Among individuals receiving TNF-α inhibitors, mycobacterium tuberculosis accounts for 12.5–59% of all infections; pneumocystis jirovecii constitutes 20% of all non-viral infections; and the incidence of legionella pneumophila infections is 13–21 times higher compared to the general population [7].